Literature DB >> 15629253

An overview on biological mechanisms of PPARs.

Bhavani Prasad Kota1, Tom Hsun-Wei Huang, Basil D Roufogalis.   

Abstract

Peroxisome proliferator activated receptors (PPARs) are transcriptional factors belonging to the ligand-activated nuclear receptor superfamily. They are ubiquitously expressed throughout the body. On activation by endogenously secreted prostaglandins and fatty acids, they initiate transcription of an array of genes that are involved in energy homeostasis. So far, three major types have been identified, namely PPAR-alpha, PPAR-beta/delta and PPAR-gamma. PPAR-alpha and PPAR-gamma are crucial for lipid and glucose metabolism, respectively. Although limited information is available on PPAR-beta biological functions, recent studies have shown that PPAR-beta also regulates glucose metabolism and fatty acid oxidation. The discovery of PPAR-alpha agonists such as fibrates and PPAR-gamma agonists such as thiozolidinediones enables recognition of the mechanisms involved in ameliorating the adverse effects of chronic disorders such as atherosclerosis and diabetes. In addition, PPARs are also involved in the regulation of various types of tumours, inflammation, cardiovascular diseases and infertility. The importance of these transcription factors in physiology and pathophysiology has instigated much research in this field. In this article, structural features of PPARs, their gene transcription mechanisms and recent developments in the discovery of their biological functions are reviewed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15629253     DOI: 10.1016/j.phrs.2004.07.012

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  186 in total

1.  PPAR signaling pathway and cancer-related proteins are involved in celiac disease-associated tissue damage.

Authors:  Maria Paola Simula; Renato Cannizzaro; Vincenzo Canzonieri; Alessandro Pavan; Stefania Maiero; Giuseppe Toffoli; Valli De Re
Journal:  Mol Med       Date:  2010-03-03       Impact factor: 6.354

2.  Inducing effect of clofibric acid on stearoyl-CoA desaturase in intestinal mucosa of rats.

Authors:  Tohru Yamazaki; Makiko Kadokura; Yuki Mutoh; Takeshi Sakamoto; Mari Okazaki; Atsushi Mitsumoto; Yoichi Kawashima; Naomi Kudo
Journal:  Lipids       Date:  2014-11-02       Impact factor: 1.880

Review 3.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

Review 4.  Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders.

Authors:  Pitchai Balakumar; Sonam Kathuria
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

5.  Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without Type 2 diabetes.

Authors:  Hulya Yilmaz-Aydogan; Ozlem Kurnaz; Ozlem Kurt; Basak Akadam-Teker; Ozlem Kucukhuseyin; Atike Tekeli; Turgay Isbir
Journal:  Mol Cell Biochem       Date:  2011-07-21       Impact factor: 3.396

6.  Resveratrol upregulated SIRT1, FOXO1, and adiponectin and downregulated PPARγ1-3 mRNA expression in human visceral adipocytes.

Authors:  Cíntia dos Santos Costa; Francieli Rohden; Thais Ortiz Hammes; Rogério Margis; Josiane Woutheres Bortolotto; Alexandre Vontobel Padoin; Cláudio Cora Mottin; Regina Maria Guaragna
Journal:  Obes Surg       Date:  2011-03       Impact factor: 4.129

7.  Human urinary metabolomic profile of PPARalpha induced fatty acid beta-oxidation.

Authors:  Andrew D Patterson; Ondrej Slanar; Kristopher W Krausz; Fei Li; Constance C Höfer; Frantisek Perlík; Frank J Gonzalez; Jeffrey R Idle
Journal:  J Proteome Res       Date:  2009-09       Impact factor: 4.466

8.  New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.

Authors:  Angelika Lüdtke; Janine Buettner; Hartmut H-J Schmidt; Howard J Worman
Journal:  J Med Genet       Date:  2007-09       Impact factor: 6.318

9.  Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.

Authors:  Nicola J Sinden; Robert A Stockley
Journal:  Ther Adv Chronic Dis       Date:  2010-03       Impact factor: 5.091

10.  Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats.

Authors:  Sajay B Churi; Omar S Abdel-Aleem; Kiranjeet K Tumber; Heather Scuderi-Porter; Bradley K Taylor
Journal:  J Pain       Date:  2008-04-03       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.